Evidence-based · Longevity

Low Albumin and Longevity: What It Signals
Low albumin is tied to higher mortality in older adults. What albumin signals about inflammation and aging, and why it's a biological age marker.
Part ofThe Longevity Guide→Albumin is the workhorse protein of your bloodstream: the most abundant one there, made by the liver, and responsible for everything from holding fluid inside your vessels to ferrying hormones, drugs, and fatty acids around the body. On a standard metabolic panel it’s an afterthought, a number most people never think about. But in longevity research, a low albumin is one of the more ominous quiet signals you can carry, which is why it’s one of the nine inputs to the PhenoAge biological age calculator.
This is educational information, not medical advice. Albumin is interpreted in context by a clinician; a single value doesn’t diagnose anything on its own.

What albumin is and what moves it
Albumin makes up roughly half of the protein in your blood plasma. Normal serum levels sit around 35–50 g/L. Because the liver manufactures it and it has a relatively long half-life (about three weeks), albumin reflects your average state over time rather than a momentary blip.
Levels drift down for several distinct reasons, and untangling them is the whole game:
Albumin is the most abundant protein in your blood, a broad gauge of liver function, nutrition, and inflammation.
- Inflammation. Albumin is a negative acute-phase reactant: when the body ramps up inflammatory proteins, it dials albumin production down. Chronic low-grade inflammation quietly suppresses it.
- Poor protein status or malnutrition. Inadequate intake or absorption can lower albumin, though this is slower and less dominant than people assume.
- Liver disease. A damaged liver makes less.
- Losses. Kidney disease (protein spilling into urine) or gut disease can drain albumin.
That mix is what makes albumin such a useful summary marker, and such a poor specific one.
The mortality signal
The link between low albumin and earlier death is one of the more consistent findings in the literature. A clear recent example is the Moli-sani study, a large Italian population cohort.
Among the 3,299 participants aged 65 and older, those with hypoalbuminemia (albumin ≤35 g/L) had a 1.83-fold higher all-cause mortality risk compared with those above 40 g/L (hazard ratio 1.83, 95% CI 1.33–2.50). Over a median 13.1 years of follow-up, the cohort recorded 1,428 deaths. The risk gradient also held for specific causes: per one standard-deviation drop in albumin, cancer mortality rose (HR 1.15, 95% CI 1.02–1.30) and vascular mortality rose (HR 1.19, 95% CI 1.07–1.33).
| Albumin category (age 65+) | All-cause mortality risk |
|---|---|
| >40 g/L (reference) | 1.00 |
| ≤35 g/L (hypoalbuminemia) | 1.83 (95% CI 1.33–2.50) |
Hypoalbuminemia was far more common in the older group (3.6%) than in younger participants (1.0%), one reason albumin tends to feed into age-related risk models.

Inflammation, not just the plate
The tempting interpretation is “low albumin means poor nutrition, so eat more protein.” The Moli-sani authors pushed back on exactly that. They found no meaningful nutritional differences across albumin categories, and concluded that hypoalbuminemia likely functions as a marker of low-grade systemic inflammation rather than of malnutrition alone.
This reframes what a low albumin is telling you. Rather than a simple protein-intake gauge, it behaves like a slow-moving readout of chronic inflammatory burden, the same underlying process implicated in cardiovascular disease, cancer, and frailty. If that inflammatory thread interests you, our overview of inflammation markers, hs-CRP, and aging covers how these signals overlap. Albumin and CRP often move in opposite directions for the same reason: one is a negative acute-phase reactant, the other a positive one.
One caveat matters most: these are observational associations. Low albumin predicts risk, but that doesn’t mean raising albumin with, say, infusions or protein shakes lowers your risk. The albumin is a symptom of the underlying state, not the lever.
Why albumin is a biological-age marker
Albumin’s breadth is exactly why it appears in biological-age scoring. When Levine and colleagues built the PhenoAge model, they screened 42 clinical markers against 23 years of mortality follow-up in NHANES III and narrowed the field to nine biomarkers plus chronological age. Albumin survived that cut, alongside creatinine, glucose, C-reactive protein, lymphocyte percentage, mean cell volume, red cell distribution width, alkaline phosphatase, and white blood cell count.
In the PhenoAge equation, higher albumin pulls your estimated age down. It’s protective in the model. That’s consistent with the epidemiology: healthy albumin tracks with lower mortality risk. For the wider set of markers worth watching, see which biomarkers of aging are worth tracking.

Reading your own albumin
- A value comfortably in the 40s (g/L) is reassuring; a persistent drift toward or below 35 g/L in an older adult is worth a conversation with your clinician.
- Look at the trend, not one reading. Albumin’s long half-life makes a downward trajectory more meaningful than a single sample.
- Interpret it alongside inflammation and liver/kidney markers. Low albumin plus high CRP paints a different picture than low albumin with clear protein loss in the urine.
- Don’t chase the number directly. The goal is to identify and address whatever is suppressing it (chronic inflammation, disease, or genuine undernutrition), not to force albumin up in isolation.
The takeaway
Albumin is a broad, slow-moving barometer of how the body is doing overall: liver output, protein status, and, above all, chronic inflammation. A low value in an older adult is a well-validated signal of elevated mortality risk, which is why it belongs in biological-age models. But it’s a marker, not a target: the useful move is to ask why it’s low, not to inflate the number. To see how albumin combines with the other eight markers into a single readout, run your labs through the PhenoAge biological age calculator.
Sources
- Di Castelnuovo A, et al. The association between hypoalbuminemia and risk of death due to cancer and vascular disease in individuals aged 65 years and older: the Moli-sani study. 2024 (PMC11247150)
- Levine ME, et al. An epigenetic biomarker of aging for lifespan and healthspan. Aging. 2018 (PMC5940111)
References
Stay current
Get evidence-based briefings in your inbox.